Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

• Sara M Mangsbo,
• Eivind Hovig,
• Nadia Mensali,
• Else Marit Inderberg,
• Steinar Aamdal,
• Elin Aamdal,
• Tormod Guren,
• Gustav Gaudernack,
• Espen Basmo Ellingsen,
• Wolfgang Lilleby,
• Paal F Brunsvig

Affiliations

Sara M Mangsbo

Aff1 grid.8993.b0000000419369457Immunology, Genetics and PathologyIGP, Uppsala University Uppsala Sweden

Eivind Hovig

2Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Part of Oslo University Hospital, Oslo, Norway

Nadia Mensali

Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway

Else Marit Inderberg

Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway

Steinar Aamdal

1Ultimovacs ASA, Oslo, Norway

Elin Aamdal

4Oslo University Hospital, Oslo, Norway

Tormod Guren

4Oslo University Hospital, Oslo, Norway

Gustav Gaudernack

1Ultimovacs ASA, Oslo, Norway

Espen Basmo Ellingsen

Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

Wolfgang Lilleby

Department of Oncology, Oslo University Hospital, Oslo, Norway

Paal F Brunsvig

Department of Oncology, Oslo University Hospital, Oslo, Norway